RT Journal Article
SR Electronic
T1 CANCER CHEMOTHERAPY AND DRUG METABOLISM
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP 1083
OP 1096
DO 10.1124/dmd.105.004374
VO 33
IS 8
A1 David S. Riddick
A1 Chunja Lee
A1 Shairoz Ramji
A1 Edwin C. Chinje
A1 Rachel L. Cowen
A1 Kaye J. Williams
A1 Adam V. Patterson
A1 Ian J. Stratford
A1 Charles S. Morrow
A1 Alan J. Townsend
A1 Youssef Jounaidi
A1 Chong-Sheng Chen
A1 Ting Su
A1 Hong Lu
A1 Pamela S. Schwartz
A1 David J. Waxman
YR 2005
UL http://dmd.aspetjournals.org/content/33/8/1083.abstract
AB Drug-metabolizing enzymes and drug transporters are key determinants of the pharmacokinetics and pharmacodynamics of many antineoplastic agents. Metabolism and transport influence the cytotoxic effects of antineoplastic agents in target tumor cells and normal host tissues. This article summarizes several state-of-the-art approaches to enhancing the effectiveness and safety of cancer therapy based on recent developments in our understanding of antineoplastic drug metabolism and transport. Advances in four interrelated research areas presented at a recent symposium sponsored by the Division for Drug Metabolism of the American Society for Pharmacology and Experimental Therapeutics (Experimental Biology 2004; Washington D.C., April 17–21, 2004) are discussed: 1) interactions of anthracyclines with drug-metabolizing enzymes; 2) use of hypoxia-selective gene-directed enzyme prodrug therapy (GDEPT) in combination with bioreductive prodrugs; 3) synergy between glutathione conjugation and conjugate efflux in conferring resistance to electrophilic toxins; and 4) use of cytochromes P450 as prodrug-activating enzymes in GDEPT strategies. A clear theme emerged from this symposium: drug metabolism and transport processes can be modulated and exploited in ways that may offer distinct therapeutic advantages in the management of patients with cancer. The American Society for Pharmacology and Experimental Therapeutics